Results 131 to 140 of about 6,532 (197)

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Eur Respir J
Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA.   +13 more
europepmc   +1 more source

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

Highly Effective Modulator Therapy in Cystic Fibrosis: Addressing Unusual Variants in the Middle East. [PDF]

Pulm Med
Isse S, Wahla AS, Uzbeck MH, Zoumot Z, Abuzakouk M, Shafiq I.   +5 more
europepmc   +1 more source

The cystic fibrosis airway cytokine interleukin-1β enhances cystic fibrosis transmembrane conductance regulator modulator efficacy. [PDF]

ERJ Open Res
Gentzsch M, Boyles SE, Minges JT, Cholon DM, Okuda K, Ribeiro CMP.   +5 more
europepmc   +1 more source

AI-driven breathomics for early detection of CFTR modulator resistance in cystic fibrosis. [PDF]

Ann Med Surg (Lond)
Khan MH, Tariq AU, Cheema WA, Fatima M.
europepmc   +1 more source

Considerations for early life genetic therapies in cystic fibrosis. [PDF]

Am J Physiol Lung Cell Mol Physiol
Cooney AL, Thornell IM, Pezzulo AA, Fischer AJ, Cook DP, Abou Alaiwa MH, Larson Ode KM, Uc A, Zabner J, Ryan AL, Stoltz DA, Sinn PL, McCray PB, Meyerholz DK.   +13 more
europepmc   +1 more source

Quantitative Systems Toxicology Predicts Ivacaftor-Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity. [PDF]

Clin Pharmacol Ther
Shi A, Cornwell C, Yang K, Beringer PM.
europepmc   +1 more source